Rallybio Corp (RLYB): Price and Financial Metrics
GET POWR RATINGS... FREE!
RLYB Stock Price Chart Interactive Chart >
RLYB Price/Volume Stats
|Current price||$13.00||52-week high||$25.78|
|Prev. close||$13.00||52-week low||$6.74|
|Day high||$13.18||Avg. volume||106,826|
|50-day MA||$9.50||Dividend yield||N/A|
|200-day MA||$12.16||Market Cap||417.70M|
Rallybio Corp (RLYB) Company Bio
Rallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a preclinical-stage monoclonal anti-HPA-1a antibody for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT). The company is also developing RLYB211, a polyclonal anti-HPA-1a antibody that is in a Phase 1/2 clinical trial for the prevention of FNAIT; RLYB114, a pegylated C5 inhibitor in preclinical development for the treatment of complement-mediated ophthalmic diseases; and RLYB116, a subcutaneously administered inhibitor of complement factor 5, or C5, for the treatment of patients with paroxysmal nocturnal hemoglobinuria and generalized myasthenia gravis. The company also has discovery-stage programs that are focused on the identification of small molecule therapeutics for patients with rare metabolic diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases. Rallybio Corporation was incorporated in 2018 and is headquartered in New Haven, Connecticut. Rallybio Corporation operates as a subsidiary of Rallybio Holdings, LLC.
Most Popular Stories View All
RLYB Latest News Stream
|Loading, please wait...|
RLYB Latest Social Stream
View Full RLYB Social Stream
Latest RLYB News From Around the Web
Below are the latest news stories about Rallybio Corp that investors may wish to consider to help them evaluate RLYB as an investment opportunity.
Great news for Rallybio Corporation (NASDAQ:RLYB): Insiders acquired stock in large numbers last year
It is usually uneventful when a single insider buys stock. However, When quite a few insiders buy shares, as it...
NEW HAVEN, Conn., January 18, 2022--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that Ami Bavishi has joined as the company’s Head of Investor Relations and Corporate Communications.
NEW HAVEN, Conn., January 06, 2022--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today provided an update on recent accomplishments and announced expected upcoming milestones. The Company will present these updates at the 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022 at 11:15 a.m. ET.
Rallybio (RLYB) has been struggling lately, but the selling pressure may be coming to an end soon.
Equities analysts expect Rallybio Corp (NASDAQ:RLYB) to report earnings of ($0.41) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Rallybios earnings, with the highest EPS estimate coming in at ($0.38) and the lowest estimate coming in at ($0.43). The firm is scheduled to issue its next 
RLYB Price Returns